A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

Trial Profile

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Acalabrutinib (Primary) ; Pembrolizumab
  • Indications B cell lymphoma
  • Focus Adverse reactions; Proof of concept
  • Acronyms KEYNOTE145
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 19 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Jul 2016 Planned number of patients changed from 324 to 187.
    • 22 Jul 2016 Planned End Date changed from 1 May 2018 to 1 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top